Below is a display of the safety results of the adequate and well-controlled studies of RYBELSUS (referred to below as semaglutide tablets) in adult patients with type 2 diabetes mellitus
Most patients experience gastrointestinal symptoms, including diarrhea, during the initial weeks of treatment or when doses are increased
Medical supervision requirement: All AOD-9604 therapy requires comprehensive physician oversight including baseline health assessment and laboratory work, informed consent regarding research-purposes-only status, regular monitoring of body composition and metabolic markers, dose adjustments based on individual response, and integration with comprehensive health optimization strategies
Injectables are usually refrigerated before first use and can lose their effectiveness if exposed to extreme heat or freezing temperatures
Answer: Semaglutide for weight management is generally indicated for adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related condition such as high blood pressure, type 2 diabetes, or insulin resistance